REG - Oxford Biomedica PLC - Grant of Options
04/10/2023 17:15
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231004:nRSD7269Oa&default-theme=true
RNS Number : 7269O Oxford Biomedica PLC 04 October 2023
Grant of options
London, UK - 04 October 2023: Oxford Biomedica plc ("Oxford Biomedica" or "the
Company") (LSE: OXB) announces that on 04 October 2023 nil-cost share options
over ordinary shares of 50 pence each in the Company were granted under the
Oxford Biomedica 2015 Deferred Bonus Plan ("DBP") and the Oxford Biomedica
2015 Long Term Incentive Plan ("LTIP").
2023 LTIP and 2022 DBP Awards
Name of individual Title Number of shares subject to the 2022 DBP award Number of shares subject to the 2023 LTIP award Total shares over which options now held Percentage of current issued share capital under option
Frank Mathias Chief Executive Officer - 323,178 323,178 0.334%
Stuart Paynter Chief Financial Officer 63,869 142,469 538,211 0.556%
Sebastien Ribault Chief Commercial Officer 66,903 66,903 0.069%
Mark Caswell Site Head US Operations 74,172 74,172 0.077%
Lisa James Chief People Officer 15,887 39,670 99,989 0.103%
James Miskin Chief Technical Officer 32,189 56,262 215,035 0.222%
Kyriacos Mitrophanous Chief Scientific Officer 35,256 57,906 277,856 0.287%
Madduri Ravi Rao Chief Medical Officer 21,129 50,135 131,400 0.136%
Matthew Treagus Chief Information Officer and Chief of Staff 32,468 54,433 143,648 0.148%
Natalie Walter General Counsel 27,897 48,069 167,244 0.173%
Under the terms of the DBP plan, the DBP awards will become exercisable as to
one third of the shares subject to each award on each of the first three
anniversaries of the grant date.
In line with best practice and current investor guidance the quantum of the
2023 LTIP to Frank Mathias was scaled back from 200% of salary to 160% of
salary and for Stuart Paynter the quantum of the 2023 LTIP was scaled back by
30% from 175% of salary to 122.5% of salary. The quantum of 2023 LTIP granted
to other new members of SET was scaled back by 20%, all other members of the
set had their awards scaled back by 30%
The LTIP awards are subject to performance conditions. As set out in the 2022
Directors' Remuneration Report, the performance condition is based on TSR (40%
of the award, assessed over the three years from grant); revenue growth (40%
of the award, assessed over financial years 2023, 2024 and 2025) and strategic
milestones (20% of the award). Details of the measures are included in the
2022 Directors' Remuneration Report, other than as regards the strategic
milestones, which are commercially sensitive and will be disclosed in due
course.
The LTIP awards granted to Frank Mathias and Stuart Paynter will "vest"
following the assessment of the performance condition, but will only be
"released" so that they can be exercised following the end of a further two
year holding period. The 2023 awards granted to other participants will vest
and be released following the assessment of the performance condition.
The Notification of Dealing Forms set out below are provided in accordance
with the requirements of the EU Market Abuse Regulation.
Notification of Dealing Form
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Frank Mathias
2. Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2023 LTIP Award
Price Volume
Nil 323,178
d) Aggregated information
- Aggregate volume Awards granted over 323,178 shares in total
- Price
N/A
e) Date of the transaction 2023-10-04
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 323,178 shares in total
N/A
e)
Date of the transaction
2023-10-04
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Stuart Paynter
2. Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration was paid for the grant of
awards.
c) Price(s) and volumes(s) 2023 LTIP Award
Price Volume
Nil 142,469
2022 DBP Award
Price Volume
Nil 63,869
d) Aggregated information
- Aggregate volume Awards granted over 206,338 shares in total
- Price
N/A
e) Date of the transaction 2023-10-04
f) Place of the transaction Outside of trading venue
2022 DBP Award
Price Volume
Nil 63,869
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 206,338 shares in total
N/A
e)
Date of the transaction
2023-10-04
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Sebastien Ribault
2. Reason for the notification
a) Position/status Chief Commercial Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2023 LTIP Award
Price Volume
Nil 66,903
d) Aggregated information
- Aggregate volume Awards granted over 66,903 shares in total
- Price
N/A
e) Date of the transaction 2023-10-04
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 66,903 shares in total
N/A
e)
Date of the transaction
2023-10-04
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Mark Caswell
2. Reason for the notification
a) Position/status Site Head of US Operations
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2023 LTIP Award
Price Volume
Nil 74,172
d) Aggregated information
- Aggregate volume Awards granted over 74,172 shares in total
- Price
N/A
e) Date of the transaction 2023-10-04
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 74,172 shares in total
N/A
e)
Date of the transaction
2023-10-04
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Lisa James
2. Reason for the notification
a) Position/status Chief People Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration was paid for the grant of
awards.
c) Price(s) and volumes(s) 2023 LTIP Award
Price Volume
Nil 39,670
2022 DBP Award
Price Volume
Nil 15,887
d) Aggregated information
- Aggregate volume Awards granted over 55,557 shares in total
- Price
N/A
e) Date of the transaction 2023-10-04
f) Place of the transaction Outside of trading venue
2022 DBP Award
Price Volume
Nil 15,887
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 55,557 shares in total
N/A
e)
Date of the transaction
2023-10-04
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name James Miskin
2. Reason for the notification
a) Position/status Chief Technical Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration was paid for the grant of
awards.
c) Price(s) and volumes(s) 2023 LTIP Award
Price Volume
Nil 56,262
2022 DBP Award
Price Volume
Nil 32,189
d) Aggregated information
- Aggregate volume Awards granted over 88,451 shares in total
- Price
N/A
e) Date of the transaction 2023-10-04
f) Place of the transaction Outside of trading venue
2022 DBP Award
Price Volume
Nil 32,189
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 88,451 shares in total
N/A
e)
Date of the transaction
2023-10-04
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Kyriacos Mitrophanous
2. Reason for the notification
a) Position/status Chief Scientific Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration was paid for the grant of
awards.
c) Price(s) and volumes(s) 2023 LTIP Award
Price Volume
Nil 57,906
2022 DBP Award
Price Volume
Nil 35,256
d) Aggregated information
- Aggregate volume Awards granted over 93,162 shares in total
- Price
N/A
e) Date of the transaction 2023-10-04
f) Place of the transaction Outside of trading venue
2022 DBP Award
Price Volume
Nil 35,256
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 93,162 shares in total
N/A
e)
Date of the transaction
2023-10-04
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Madduri Rao
2. Reason for the notification
a) Position/status Chief Medical Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration was paid for the grant of
awards.
c) Price(s) and volumes(s) 2023 LTIP Award
Price Volume
Nil 50,135
2022 DBP Award
Price Volume
Nil 21,129
d) Aggregated information
- Aggregate volume Awards granted over 71,264 shares in total
- Price
N/A
e) Date of the transaction 2023-10-04
f) Place of the transaction Outside of trading venue
2022 DBP Award
Price Volume
Nil 21,129
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 71,264 shares in total
N/A
e)
Date of the transaction
2023-10-04
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Matthew Treagus
2. Reason for the notification
a) Position/status Chief Information Officer and Chief of Staff
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration was paid for the grant of
awards.
c) Price(s) and volumes(s) 2023 LTIP Award
Price Volume
Nil 54,433
2022 DBP Award
Price Volume
Nil 32,468
d) Aggregated information
- Aggregate volume Awards granted over 86,901 shares in total
- Price
N/A
e) Date of the transaction 2023-10-04
f) Place of the transaction Outside of trading venue
2022 DBP Award
Price Volume
Nil 32,468
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 86,901 shares in total
N/A
e)
Date of the transaction
2023-10-04
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Natalie Walter
2. Reason for the notification
a) Position/status General Counsel
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration was paid for the grant of
awards.
c) Price(s) and volumes(s) 2023 LTIP Award
Price Volume
Nil 48,069
2022 DBP Award
Price Volume
Nil 27,897
d) Aggregated information
- Aggregate volume Awards granted over 75,966 shares in total
- Price
N/A
e) Date of the transaction 2023-10-04
f) Place of the transaction Outside of trading venue
2022 DBP Award
Price Volume
Nil 27,897
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 75,966 shares in total
N/A
e)
Date of the transaction
2023-10-04
f)
Place of the transaction
Outside of trading venue
-Ends-
For further information, please contact:
Oxford Biomedica plc: Tel: +44 (0)1865 783 000
Natalie Walter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene
therapy CDMO with a mission to enable its clients to deliver life changing
therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more
than 25 years of experience in viral vectors; the driving force behind the
majority of gene therapies. The Company collaborates with some of the world's
most innovative pharmaceutical and biotechnology companies, providing viral
vector development and manufacturing expertise in lentivirus, adeno-associated
virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class
capabilities span from early-stage development to commercialisation. These
capabilities are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It
has locations across Oxfordshire, UK and near Boston, MA, US. Learn more
at www.oxb.com (https://www.oxb.com/) , www.oxbsolutions.com
(https://oxbsolutions.com/) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica/) and YouTube
(https://www.youtube.com/user/OxfordBioMedica) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHGZMGGVDNGFZMRecent news on Oxford BioMedica
See all newsREG - Oxford Biomedica PLC - Total Voting Rights
AnnouncementREG - Oxford Biomedica PLC - 2023 Annual Report and Accounts
AnnouncementREG - Oxford Biomedica PLC - Total Voting Rights
AnnouncementREG - Oxford Biomedica PLC - Update on CDMO Services
AnnouncementREG - Oxford Biomedica PLC - Board Changes
Announcement